Mineralys Therapeutics (NASDAQ:MLYS) CFO Adam Scott Levy Sells 10,758 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy sold 10,758 shares of the stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $42.01, for a total value of $451,943.58. Following the transaction, the chief financial officer directly owned 116,865 shares of the company’s stock, valued at approximately $4,909,498.65. The trade was a 8.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Adam Scott Levy also recently made the following trade(s):

• On Wednesday, July 30th, Adam Scott Levy sold 59,925 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $14.76, for a total transaction of $884,493.00.
• On Tuesday, July 29th, Adam Scott Levy sold 807 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $14.00, for a total transaction of $11,298.00.
• On Monday, July 28th, Adam Scott Levy sold 12,946 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $14.04, for a total value of $181,761.84.

Mineralys Therapeutics Stock Up 1.3%

MLYS opened at $43.35 on Thursday. The business has a fifty day moving average of $29.55 and a 200 day moving average of $19.58. Mineralys Therapeutics, Inc. has a 52-week low of $8.24 and a 52-week high of $44.38. The stock has a market cap of $2.87 billion, a P/E ratio of -12.18 and a beta of 0.40.

Mineralys Therapeutics (NASDAQ:MLYS) last released its earnings results on Tuesday, August 12th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.12. Equities analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Institutional Investors Weigh In On Mineralys Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. boosted its position in Mineralys Therapeutics by 297.5% during the first quarter. SBI Securities Co. Ltd. now owns 1,590 shares of the company’s stock valued at $25,000 after purchasing an additional 1,190 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Mineralys Therapeutics by 51.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company’s stock worth $34,000 after acquiring an additional 850 shares in the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Mineralys Therapeutics by 42.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company’s stock worth $54,000 after acquiring an additional 1,197 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Mineralys Therapeutics during the 2nd quarter worth approximately $91,000. Finally, Quarry LP bought a new position in shares of Mineralys Therapeutics during the 1st quarter worth approximately $111,000. Institutional investors own 84.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on MLYS shares. Bank of America upped their target price on shares of Mineralys Therapeutics from $38.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Wednesday, October 8th. Wall Street Zen raised Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 22nd. HC Wainwright restated a “buy” rating and set a $42.00 price target on shares of Mineralys Therapeutics in a research note on Monday, September 8th. Finally, Wells Fargo & Company increased their target price on shares of Mineralys Therapeutics from $26.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, September 11th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Mineralys Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $43.50.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.